Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P20020 (
adenosine triphosphatase
)
3,299
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
This study investigated the effect of dexamethasone (DEX) on intracellular calcium levels and the expressions of transient receptor potential cation channel subcomponent V member 6 (
TRPV6
), sodium-calcium exchanger 1 (
NCX1
), and
plasma membrane calcium ATPase 1
(
PMCA1
) in A549 cells. The intracellular calcium level, by using the calcium indicator pGP-CMV-GCaMP6f, increased following DEX treatment for 6, 12, and 24 h in A549 cells. In addition, Rhod-4 assay after DEX treatment for 24 h showed that DEX increased the level of intracellular calcium. The expression of the calcium influx
TRPV6
gene significantly increased, whereas the expressions of the calcium outflow
NCX1
and
PMCA1
genes significantly decreased with DEX treatment. The mRNA levels of surfactant protein genes
SFTPA1
,
SFTPB
,
SFTPC
, and
SFTPD
and the secreted airway mucin genes
MUC1
and
MUC5AC
were investigated by treating cells with DEX. The DEX treatment decreased the mRNA levels of
SFTPA1
and
SFTPB
but increased the mRNA levels of
SFTPC
and
SFTPD
. The
MUC1
mRNA level was increased by DEX treatment, whereas
MUC5AC
mRNA was significantly decreased. These results indicate that DEX influences the intracellular calcium level through
TRPV6
, and affects pulmonary surfactant genes and secreted airway mucin genes in A549 cells.
...
PMID:Dexamethasone Treatment Increases the Intracellular Calcium Level Through
TRPV6
in A549 Cells. 3203 37